Raymond Barnhill

Prof. Raymond Barnhill

Department of Translational Research, Institut Curie, 75005 Paris, France

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2021 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
JBJeremy Bigot
Jeremy Bigot
ALAna I. Lalanne
Ana I. Lalanne
FLFrancesca Lucibello
Francesca Lucibello
PGPaul Gueguen
Paul Gueguen
AHAlexandre Houy
Alexandre Houy
OLOlivier Lantz
Olivier Lantz
Disruption of splicing patterns due to mutations of genes coding splicing factors in tumors represents a potential source of tumor neoantigens, which would be both public (shared between patients) and tumor-specific (not expressed in normal tissues). In this study, we show that mutations of the splicing factor SF3B1 in uveal melanoma generate such immunogenic neoantigens. Memory CD8+ T cells specific for these neoantigens are preferentially found in 20% of patients with uveal melanoma bearing SF3B1-mutated tumors. Single-cell analyses of neoepitope-specific T cells from the blood identified large clonal T-cell expansions, with distinct effector transcription patterns. Some of these expanded T-cell receptors are also present in the corresponding tumors. CD8+ T-cell clones specific for the neoepitopes specifically recognize and kill SF3B1-mutated tumor cells, supporting the use of this new family of neoantigens as therapeutic targets. Significance: Mutations of the splicing factor SF3B1 in uveal melanoma generate shared neoantigens that are uniquely expressed by tumor cells, leading to recognition and killing by specific CD8 T cells. Mutations in splicing factors can be sources of new therapeutic strategies applicable to diverse tumors. This article is highlighted in the In This Issue feature, p. 1861

6 April 2016 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LBLaurent A. Bentolila
Laurent A. Bentolila
RPRoshini Prakash
Roshini Prakash
DMDaniela Mihic-Probst
Daniela Mihic-Probst
MWMadhuri Wadehra
Madhuri Wadehra
HKHynda K. Kleinman
Hynda K. Kleinman
CLClaire Lugassy
Claire Lugassy
Angiotropism/pericytic mimicry and vascular co-option involve tumor cell interactions with the abluminal vascular surface. These two phenomena may be closely related. However, investigations of the two processes have developed in an independent fashion and different explanations offered as to their biological nature. Angiotropism describes the propensity of tumor cells to spread distantly via continuous migration along abluminal vascular surfaces, or extravascular migratory metastasis (EVMM). Vascular co-option has been proposed as an alternative mechanism by which tumors cells may gain access to a blood supply. We have used a murine brain melanoma model to analyze the interactions of GFP human melanoma cells injected into the mouse brain with red fluorescent lectin-labeled microvascular channels. Results have shown a striking spread of melanoma cells along preexisting microvascular channels and features of both vascular co-option and angiotropism/pericytic mimicry. This study has also documented the perivascular expression of Serpin B2 by angiotropic melanoma cells in the murine brain and in human melanoma brain metastases. Our findings suggest that vascular co-option and angiotropism/pericytic mimicry are closely related if not identical processes. Further studies are needed in order to establish whether EVMM is an alternative form of cancer metastasis in addition to intravascular cancer dissemination.

3 January 2023 in JAMA Network Open
Verified
Journal Article
Closed access
PDF file
Raymond BarnhillRaymond Barnhill
Raymond Barnhill
DEDavid E. Elder
David E. Elder
MPMichael W. Piepkorn
Michael W. Piepkorn
SKStevan R. Knezevich
Stevan R. Knezevich
LRLisa M. Reisch
Lisa M. Reisch
JEJoann G. Elmore
Joann G. Elmore
The mission of the pathologist interpreting melanoma and related melanocytic lesions is to provide an accurate and reproducible diagnosis to health care practitioners and their patients. This diagnostic report should be accessible, transparent, and understandable and should transmit relevant information regarding diagnosis and prognosis, thereby facilitating optimal treatment of patients.1 Of note, a 2021 survey of practicing pathologists in the US has suggested that communication of such diagnostic information would be improved with less confusion via a more standardized reporting system.2

22 July 2019 in Cancers
Verified
Journal Article
Open access
PDF file
Manuel RodriguesManuel Rodrigues
Manuel Rodrigues
LKLeanne de Koning
Leanne de Koning
SCSarah E. Coupland
Sarah E. Coupland
AJAart G. Jochemsen
Aart G. Jochemsen
RMRichard Marais
Richard Marais
TCthe UM Cure 2020 Consortium
the UM Cure 2020 Consortium
Despite much progress in our understanding of uveal melanoma (UM) over the past decades, this rare tumour is still often misclassified. Although UM, like other melanomas, is very probably derived from melanocytes, it is drastically different from cutaneous melanoma and most other melanoma subtypes in terms of epidemiology, aetiology, biology and clinical features, including an intriguing metastatic hepatotropism. UM carries distinctive prognostic chromosome alterations, somatic mutations and gene expression profiles, allowing an active tailored surveillance strategy and dedicated adjuvant clinical trials. There is no standard systemic treatment for disseminated UM at present. In contrast to cutaneous melanoma, UMs are not BRAF-mutated, thus curtailing the use of B-Raf inhibitors. Although these tumours are characterised by some immune infiltrates, immune checkpoint inhibitors are rarely effective, possibly due to a low mutation burden. UM patients across the world not only face rare cancer-related issues (e.g., specific management strategies, access to information and to expert centres), but also specific UM problems, which can be exacerbated by the common misconception that it is a subtype of cutaneous melanoma. As a European Consortium dedicated to research on UM and awareness on the disease, “UM Cure 2020” participants urge medical oncologists, pharmaceutical companies, and regulatory agencies to acknowledge UM as a melanoma with specific issues, in order to accelerate the development of new therapies for patients.

23 August 2018 in The Journal of Pathology: Clinical Research
Verified
Journal Article
Open access
PDF file
Raymond BarnhillRaymond Barnhill
Raymond Barnhill
PVPeter Vermeulen
Peter Vermeulen
SDSofie Daelemans
Sofie Daelemans
PDPieter-Jan Van Dam
Pieter-Jan Van Dam
SRSergio Roman‐Roman
Sergio Roman‐Roman
CLClaire Lugassy
Claire Lugassy
Up to 50% of uveal melanomas (UM) metastasise to the liver within 10 years of diagnosis, and these almost always prove rapidly fatal. As histopathological growth patterns (HGPs) of liver metastases of the replacement and desmoplastic type, particularly from colon and breast carcinoma, may import valuable biological and prognostic information, we have studied HGP in a series of 41 UM liver metastases originating from 41 patients from the period 2006–2017. Twenty patients underwent enucleation while 21 had radiation therapy. Analysis of UM by array comparative genomic hybridisation revealed: 25 (64%) patients with high risk (monosomy3/8q gain); 13 (33%) intermediate risk (M3/8normal or disomy3/8q gain); and 1 low risk (disomy3/8normal). The principal HGP was replacement in 30 (73%) cases and desmoplastic in 11 (27%) cases. Cases with replacement demonstrated striking vascular co‐option/angiotropism. With the development of liver metastasis, only the replacement pattern, largest primary tumour diameter, and R2 (incomplete resection) status predicted diminished overall survival (OS; p < 0.041, p < 0.017, p < 0.047, respectively). On multivariate analysis, only HGP (hazard ratio; HR = 6.51, p = 0.008) and resection status remained significant. The genomic high‐risk variable had no prognostic value at this stage of liver metastasis. Chi‐square test showed no association of HGP with monosomy 3 or 8q gain. Eighteen of 41 (44%) patients are alive with disease and 23 (56%) patients died with follow‐up ranging from 12 to 318 months (mean: 70 months, median: 47 months). In conclusion, we report for the first time the frequency of the replacement and desmoplastic HGPs in liver UM metastases resected from living patients, and their potential important prognostic value for UM patients, as in other solid cancers. These results may potentially be utilised to develop radiological correlates and therapeutic targets for following and treating patients with UM metastases.

18 April 2020 in The Journal of Pathology: Clinical Research
Verified
Journal Article
Open access
PDF file
Raymond BarnhillRaymond Barnhill
Raymond Barnhill
PDPieter‐Jan van Dam
Pieter‐Jan van Dam
PVPeter Vermeulen
Peter Vermeulen
GCGabriel Champenois
Gabriel Champenois
ANAndré Nicolas
André Nicolas
CLclaire lugassy
claire lugassy
Among visceral metastatic sites, cutaneous melanoma (CM) metastasises initially to the liver in ~14–20% of cases. Liver metastases in CM patients are associated with both poor prognosis and poor response to immunotherapy. Histopathological growth patterns (HGPs) of liver metastases of the replacement and desmoplastic type, particularly from colorectal cancer and uveal melanoma (UM), may impart valuable biological and prognostic information. Here, we have studied HGP in 43 CM liver metastases resected from 42 CM patients along with other prognostic factors from three institutions. The HGPs (replacement, desmoplastic, pushing) were scored at the metastasis–liver interface with two algorithms: (1) 100% desmoplastic growth pattern (dHGP) and any (≥1%) replacement pattern (any‐rHGP) and (2) >50% dHGP, >50% rHGP or mixed (<50% dHGP and/or rHGP, pushing HGP). For 1 patient with 2 metastases, an average was taken to obtain 1 final HGP yielding 42 observations from 42 patients. 22 cases (52%) had 100% dHGP whereas 20 (48%) had any replacement. Cases with rHGP demonstrated vascular co‐option/angiotropism. With the development of liver metastasis, only rHGP (both algorithms), male gender and positive resection margins predicted diminished overall survival (p = 0.00099 and p = 0.0015; p = 0.034 and p = 0.024 respectively). On multivariate analysis, only HGP remained significant. 7 of 42 (17%) patients were alive with disease and 21 (50%) died with follow‐up after liver metastases ranging from 1.8 to 42.2 months (mean: 20.4 months, median: 19.0 months). 14 (33%) patients with previously‐treated metastatic disease had no evidence of disease at last follow up. In conclusion, we report for the first time replacement and desmoplastic HGPs in CM liver metastases and their prognostic value, as in UM and other solid cancers. Of particular importance, any rHGP significantly predicted diminished overall survival while 100% dHGP correlated with increased survival. These results contribute to a better understanding of the biology of CM liver metastases and potentially may be utilised in managing patients with these metastases.